Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Recruiting now · Phase 2

Conditions studied: Preeclampsia

In brief

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Key facts

Study ID

NCT06333652

Run by

Mayo Clinic

People needed

14

Starts

2026-09-01

Expected to finish

2028-12-31

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Individuals with < 34 0/7 weeks of gestation.
• Individuals with severe preeclampsia or HELLP features.

You may not qualify if…

• Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
• Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Where it is running

• Mayo Clinic Minnesota — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.